XPH’s Return Edge Shows the Limits of XBI’s Broader Reach

XPH delivered 19% higher returns than XBI over five years with half the volatility, while XBI’s 165 holdings were accompanied by a 53% maximum drawdown.

XBI offers broader biotechnology exposure through 165 holdings, but breadth did not produce the stronger investment outcome in its comparison with pharmaceutical-focused XPH. Over five years, XPH delivered 19% higher returns with half the volatility. XBI also experienced a 53% maximum drawdown, a measure of its deepest peak-to-trough decline.

That combination makes this more than a contest between healthcare labels. It illustrates the difference between owning a wider collection of companies and owning a portfolio whose underlying businesses expose investors to different risks. More holdings can spread company-specific setbacks without insulating a fund from pressures shared across its industry.

The historical evidence favors XPH on both return and price stability. It does not establish that pharmaceuticals will always outperform biotechnology, or that XPH is the right choice for every portfolio. The practical question is whether an investor wants exposure to established drug businesses or a broader collection of biotechnology opportunities—and can tolerate the path that exposure may take.

XPH’s advantage extends beyond the return figure

The five-year comparison gives XPH an advantage on more than performance alone. According to Motley Fool, XPH delivered 19% higher returns than XBI despite having half its volatility. XBI held 165 positions and recorded a 53% maximum drawdown.

Volatility describes how widely investment returns fluctuate. Lower volatility does not mean an investment cannot lose money, but it generally means a less erratic ride. In this comparison, investors did not have to accept larger fluctuations to obtain the better historical return: XPH supplied the stronger result with less variability.

The wording of the return comparison matters. The supplied figure is 19% higher returns, not a stated percentage-point advantage. Without the underlying returns and calculation method, it would be inappropriate to turn that comparison into a precise ending portfolio value or an annualized performance gap.

Even with that limitation, the central finding is clear. XPH’s historical case rests on the combination of a better return and lower volatility, rather than on either measure in isolation. That is relevant to investors who care about staying invested through market setbacks as much as maximizing their eventual gain.

More holdings do not eliminate shared biotech risks

XBI’s 165 holdings provide breadth across biotechnology. Owning a basket rather than a single company reduces dependence on any individual business. A disappointing development at one holding need not determine the outcome of the entire fund.

But diversification within an industry is different from diversification across the economy. Biotechnology companies can face overlapping pressures from financing conditions, investor appetite for uncertain future earnings, drug-development outcomes and regulatory decisions. A large collection of holdings can still move in the same direction when those shared pressures dominate.

This distinction helps explain why the holding count and the drawdown figure can coexist. XBI’s breadth is a description of its exposure, not a promise of capital protection. The supplied figures do not establish which particular force caused its historical decline, and they do not provide enough information to attribute that decline to specific holdings.

Investors should also distinguish a fund’s number of positions from how its money is distributed among them. Holding count alone cannot reveal concentration, exposure to different stages of drug development or the sensitivity of the portfolio to changing financing conditions. Those characteristics require examination of the fund’s current holdings and methodology.

The drawdown measures a different kind of risk

XBI’s 53% maximum drawdown is especially important for investors who may need to sell during a downturn. Maximum drawdown measures the largest decline from a preceding peak to a subsequent trough within the measured history. It captures the depth of a setback, rather than the average size of price fluctuations.

That makes it distinct from volatility. A fund can experience frequent price swings without suffering an equally severe sustained decline. Conversely, a damaging decline can matter greatly to an investor even when a longer-term return eventually looks acceptable.

The supplied comparison does not identify the dates of XBI’s peak and trough, its recovery time or XPH’s maximum drawdown. Those omissions prevent a full comparison of the funds’ worst historical losses. Half the volatility should not be interpreted as evidence that XPH’s maximum drawdown was also half as large.

For someone with foreseeable cash needs, the depth of a potential decline can be more consequential than a fund’s breadth. For someone able to hold through difficult periods, biotechnology exposure may remain attractive—but the ability to tolerate losses should be assessed before, not during, a severe setback.

The latest session does not settle the long-term choice

At the most recent close, as of October 2, 2026, at 20:00 GMT, XBI finished down 0.05% and XPH finished down 0.22%. The market was closed at that timestamp; these are completed-session changes, not live trading moves.

That session favored XBI on relative performance, but it does not overturn the five-year comparison. Daily changes and multiyear risk measures answer different questions. A fund can outperform its peer in a particular session while remaining behind over a longer period.

Nor do those closing moves establish a cause. They cannot, by themselves, show whether investors were responding to drug news, portfolio positioning or broader market conditions. Using a small daily difference to explain an investment thesis would go beyond the available evidence.

Match the exposure to the portfolio’s purpose

XPH’s stronger historical return and lower volatility give it the clearer evidence-based case for investors prioritizing a smoother healthcare allocation. XBI’s distinguishing feature is its broader biotechnology exposure, which may suit investors deliberately seeking that industry rather than simply choosing the historical winner.

Before deciding, investors should examine current portfolio weights, expenses, trading costs and overlap with existing investments. The comparison supplies no figures for those items, so it cannot establish which fund is cheaper to own or adds more diversification to a particular account.

The next useful test is whether the funds retain their contrasting risk profiles as their holdings and market conditions change. Past returns offer evidence, not a guarantee. For now, the lesson is narrower and actionable: XBI’s larger collection of holdings did not prevent a deep drawdown, while XPH’s pharmaceutical focus delivered the better reported five-year result with less volatility.

Key facts

• Five-year performance: XPH delivered 19% higher returns than XBI.
• Relative volatility: XPH had half XBI’s volatility.
• XBI breadth and downside: 165 holdings; 53% maximum drawdown.
• Latest completed session: XBI: -0.05%; XPH: -0.22%, as of October 2, 2026, 20:00 GMT. Closing prices omitted because the supplied currencies and exchanges were unspecified.

Frequently asked questions

How did XPH perform against XBI over five years?

XPH delivered 19% higher returns than XBI over the reported five-year period, while experiencing half its volatility. The comparison favors XPH on both performance and price stability. However, the underlying return totals were not supplied, so the result should not be restated as a percentage-point gap or a precise annualized advantage.

Does XBI’s 165-holding portfolio make it safer?

XBI’s 165 holdings spread exposure across biotechnology companies, reducing dependence on any individual business. They do not eliminate risks shared across the industry, such as financing conditions and drug-development uncertainty. Its reported 53% maximum drawdown shows that a broad portfolio within a sector can still experience a substantial decline.

What does XBI’s 53% maximum drawdown mean?

A 53% maximum drawdown means XBI suffered a decline of that size from a preceding peak to a subsequent trough within the measured history. It is not an annual return or a prediction of future losses. The supplied comparison does not specify the peak and trough dates or how long recovery took.

Is lower volatility the same as a smaller maximum drawdown?

No. Volatility measures fluctuations in returns, while maximum drawdown measures the deepest peak-to-trough decline. XPH had half XBI’s volatility in the reported comparison, but XPH’s maximum drawdown was not supplied. Investors therefore cannot infer that its worst historical decline was also half the size of XBI’s.

What did the latest market session show for XBI and XPH?

At the most recent close, as of October 2, 2026, at 20:00 GMT, XBI finished down 0.05% and XPH finished down 0.22%. Those completed-session changes favored XBI relative to XPH that day. They do not overturn the longer-term performance comparison or establish what caused either fund’s move.

Which fund better fits a healthcare allocation?

XPH has the stronger reported historical combination of return and lower volatility, while XBI offers broader biotechnology exposure. The appropriate choice depends on the investor’s desired industry exposure, loss tolerance and existing portfolio. Current holdings, expenses and trading costs also matter, but the supplied comparison does not provide figures for those factors.

Sources

• Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals — Motley Fool

Photo: eliasfalla · Pixabay Content License — source